Abstract
BackgroundHuman papillomavirus high risk (HPV-HR) type 16 is a significant risk factor for head and neck cancers (HNC) independent of tobacco and alcohol. The purpose of this study was to determine whether antibody levels to the HPV-16 oncoproteins E6 and E7 measured in sera collected at baseline (BL) prior to treatment and at two post-treatment follow-up (FU) visits were associated with HNC risk factors or prognosis.MethodsPresence of antibodies to HPV-16 E6 and E7 was evaluated in 109 newly diagnosed HNC cases with BL and FU blood samples, using the enzyme-linked immunosorbent assay (ELISA).ResultsHPV-16 E6 and/or E7 seropositive HNC cases were associated with higher risk in younger patients (≤ 55 years), more sexual partners (≥ 10), oropharyngeal cancer, worse stage at diagnosis, poorer grade, and nodal involvement. Between BL and FU (median = 8.3 months), there were decreased antibody levels for seropositive E6 (73% vs. 27%, p = 0.02) and seropositive E7 patients (65% vs. 35%, p = 0.09) with 5% of BL E6 and 35% of BL E7 seropositive patients converting to negative status at FU. Overall mortality (OM) was significantly worse among BL E6 seronegative patients than among BL seropositive patients (40.2% vs.13.6%, p = 0.01). There were no disease specific (DS) deaths among BL E6 seropositive vs. 24% in BL E6 seronegative patients (p = 0.01). BL E7 seronegative patients also had higher mortality than BL seropositive patients (OM: 38.2% vs. 20.0%, p = 0.04; DS: 22.5% vs. 5.6%, p = 0.07).ConclusionThese findings are the first to follow post-treatment OD levels of HPV-16 E6 and E7 in HNC and suggest that these HPV antibodies may be potential prognostic markers of survival in HNC patients.
Highlights
Human papillomavirus high risk (HPV-hazard ratios (HR)) type 16 is a significant risk factor for head and neck cancers (HNC) independent of tobacco and alcohol
Human papillomavirus high risk (HPV-HR) DNA (28 HPV-16 and 2 HPV-33)was detected in 28% of HNC tumors and the prevalence was significantly higher in the OP compared to the oral cavity (OC), 70% versus 15% (p < 0.0001)
HNC patients with > 0/ ≤ 30 pack years had significantly higher odds ratios (ORs) for seropositivity compared to never users, whereas patients who reported heavier alcohol drinking (> 21 drinks/week) had elevated ORs compared to never drinkers
Summary
Human papillomavirus high risk (HPV-HR) type 16 is a significant risk factor for head and neck cancers (HNC) independent of tobacco and alcohol. Human papillomavirus high risk (HPV-HR) types are causally related to cervical carcinomas [1] and a significant risk factor for approximately 26% of head and neck cancers (HNC) independent of tobacco and alcohol [2,3,4,5,6,7]. Antibodies to HPV-HR oncoproteins E6 and E7 are late markers for HPV-associated carcinoma with antibody prevalence increasing with clinical stage [17,18,15] These tumors show constitutively high-level E6/E7 expression due to increased mRNA transcription and stability. Invasion of the E6/E7-overexpressed tumor cells beyond the mucosa brings them in tight contact with cells of the immune system and may lead to enhanced antigenic presentation and the induction of E6/E7 antibodies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.